Table 1.
Comparison of clinical variables between treatment subgroups
| Variables | Starter n= 10 (20%) | Add-on n= 29 (58%) | Monotherapy n= 11(22%) | Total sample n=50 |
|---|---|---|---|---|
| Age (years) | 52.5±17.5 | 54.9±12.8 | 55.5±16.5 | 54.6±14.4 |
| Gender (M:F) | 3 (30%); 7(70%) | 11(37.9%); 18(62.1%) | 3 (27.3%); 8 (72.7%) | 17(34%); 33(66%) |
| Age at onset (years) | 35.9±16.9 | 34.2±11.8 | 44.6±18.1 | 36.8±14.7 |
| Education | ||||
| Secondary school | 4 (40%) | 7 (24.1%) | 0 (0%) | 11 (22%) |
| High-school | 5 (50%) | 16 (55.2%) | 5 (54%) | 27 (54%) |
| University | 1 (10%) | 6 (20.7%) | 2 (45.5%) | 12 (24%) |
| Marital status | ||||
| Single/Divorced | 4 (40%) | 15 (51.75) | 4 (36.4%) | 23 (46%) |
| Married/Engaged | 6 (60%) | 14 (48.3%) | 7 (63.6%) | 27 (54%) |
| Professional status | ||||
| Unemployed | 2 (20%) | 1 (3.4%) | 2 (18.2%) | 5 (10%) |
| Worker part-time | 1 (14.3%) | 6 (20.7%) | 0 (0%) | 7 (14%) |
| Worker full-time | 3 (30%) | 12 (41.4%) | 6 (54.5%) | 21 (42%) |
| Retired | 4 (40%) | 10 (34.5%) | 3 (27.3%) | 17 (34%) |
| Duration of illness (months) | 199.2±194.3 | 223.8±168.0 | 130.9 ±179.2 | 198.5±176.2 |
| DUI (months) | 12.2±15.2 | 17.2±21.8 | 7.45±8.4 | 14.1±18.6 |
| Diagnosis | ||||
| Major Depressive Disorder | 4 (19%) | 13 (61.9%) | 4 (19%) | 21 (42%) |
| 0 (0%) | 2 (100%) | 0 (0%) | 2 (4%) | |
| Bipolar Disorder 1 | 2 (33%) | 3 (50%) | 1 (16.7%) | 6 (12%) |
| Bipolar Disorder 2 | 2 (25%) | 3 (37.5%) | 3 (37.5%) | 8 (16%) |
| Personality Disorder Anxiety Disorder | 2 (15.4%) | 8 (61.5%) | 3 (23.1%) | 13 (26%) |
| Pharmacological Therapy | 0 (0%) | 0(0%) | 11(100%) | 11 (26%) |
| No therapy | 4 (65.9%) | 20 (69%) | 0 (0%) | 24 (48%) |
| SSRI | 1 (4.3%) | 2 (6.9%) | 0 (0%) | 3 (5%) |
| TCAs | 2 (16.9%) | 2 (6.9%) | 0 (0%) | 4 (5%) |
| SNRI | 1 (4.3%) | 1 (3.4%) | 0 (0%) | 2 (4%) |
| BDZ | 1 (4.3%) | 1 (3.4%) | 0 (0%) | 2 (4%) |
| Lithium | 1 (4.3%) | 3 (10.3%) | 0 (0%) | 4 (8%) |
| Acido valproico | ||||
| NSF | ||||
| 1 cp die | 6 (60%) | 21 (72.4%) | 9 (81.8%) | 36 (72%) |
| 2 cp die | 4 (40%) | 8 (27.6%) | 2 (18.2%) | 14 (28%) |
| Duration of treatment (weeks) | 5.20±1.93 | 6.48±1.97 | 5.09±1.86 | 5.92±2.01 |
| First use of nutraceutical compounds (y/n) | 0 (0%); 10 (100%) | 4 (13.8%); 0 (86.2%) | 0 (0%); 11 (100%) | 4 (8%); 46 (92%) |
| Side effects (y/n) | 1 (10%); 9 (90%) | 1 (3.4%); 28 (96.6%) | 1 (9.1%); 10 (90.9%) | 3(6%), 47(94%) |
Notes: Values for categorical and continuous variables are expressed in percentages and mean ± SD, respectively. DUI: Duration of untreated illness; NSF: NAC, SAMe and Folic Acid compound; SSRI: selective serotonin reuptake inhibitor; TCS: tricyclic antidepressants; SNRI: serotoninnorepinephrine reuptake inhibitor; BDZ: benzodiazepine; CGI-S: Clinical Global Impression-Severity; CGI-I: Clinical Global Impression-Improvement.